<DOC>
	<DOCNO>NCT00129363</DOCNO>
	<brief_summary>The objective study evaluate long-term safety carvedilol pediatric patient chronic heart failure , complete Pediatric Carvedilol Study 321 . Carvedilol provide open-label therapy period least 6 month ( termination study ) SmithKline Beecham Corporation d/b/a GlaxoSmithKline ( GSK ) University Sponsor .</brief_summary>
	<brief_title>Study Evaluate Safety Twice Daily Oral Carvedilol</brief_title>
	<detailed_description>This open-label , uncontrolled , extension study design ass long-term safety carvedilol pediatric patient heart failure include following phase : 1 . Screening Phase ( coincide final maintenance Month 6 Visit 321 study 2 . Down-/Up-titration Phase 3 . Maintenance Phase 4 . Down-titration 5 . Follow-up</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Male female patient chronic symptomatic congestive heart failure ( CHF ) due systemic ventricular systolic dysfunction , receive standard heart failure therapy successfully complete maintenance phase Pediatric Carvedilol Study 321 . Parent guardian patient able willing give write informed consent . The write assent child &gt; 9 year age also require . A patient , opinion investigator , would benefit openlabel carvedilol . A patient , opinion investigator , incapable cooperating requirement study . A patient treat follow medication time entry study : Monoamine oxidase ( MAO ) inhibitor ; Calcium entry blocker ; Î± blocker , labetalol ; Disopyramide , flecainide , encainide , moricizine , propafenone ; Intravenous inotropes dobutamine intravenous vasodilator agent amrinone milrinone ; Intravenous CHF medication ( e.g . diuretic , digoxin ) ; Betablockers , doubleblind carvedilol . Uncorrected primary obstructive severe regurgitative valvular disease , nondilated ( restrictive ) hypertrophic cardiomyopathy , significant systemic ventricular outflow obstruction . A patient follow contraindication betablocker therapy : Heart rate &lt; 2nd percentile age ; Unacceptable blood pressure . Sitting ( supine infant ) systolic blood pressure must &gt; 85 mm Hg teens ; &gt; 75 mm Hg schoolaged child ; &gt; 65 mm Hg infant ; Sick sinus syndrome , second third degree atrioventricular ( AV ) block , unless treat permanent pacemaker ; History current clinical evidence moderatetosevere obstructive pulmonary disease reactive airway disease ( e.g. , asthma ) require therapy ; Unstable insulindependent diabetes mellitus . Renovascular hypertension evidence pulmonary hypertension ( pulmonary vascular resistance index &gt; 6 Wood unit m2 ) unresponsive vasodilator agent oxygen , nitroprusside , nitric oxide A patient one general exclusion criterion : Significant renal ( serum creatinine &gt; 2.0 ) , hepatic ( serum AST and/or ALT &gt; 3 time upper limit normal ) , gastrointestinal , biliary disorder could impair absorption , metabolism , excretion orally administer medication ; Endocrine disorder pheochromocytoma , active hyperthyroidism untreated hypothyroidism ; Any illness heart failure may limit survival within 1 year ( e.g . neoplasm ) ; Girls childbearing potential pregnant sexually active take adequate contraceptive precaution ( e.g. , intrauterine device [ IUD ] oral contraceptive ) . A patient receive investigational drug within precede 30 day except blinded medication Pediatric Carvedilol Study 321 . An investigational drug define agent ( placebo drug ) dispense part research study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Adolescent</keyword>
	<keyword>Adrenergic alpha-Antagonists/therapeutic use</keyword>
	<keyword>Adrenergic alpha-Antagonists/pharmacokinetics</keyword>
	<keyword>Adrenergic alpha-Antagonists/administration &amp; dosage</keyword>
	<keyword>Adrenergic beta-Antagonists/therapeutic use</keyword>
	<keyword>Adrenergic beta-Antagonists/pharmacokinetics</keyword>
	<keyword>Adrenergic beta-Antagonists/administration &amp; dosage</keyword>
	<keyword>Age Factors</keyword>
	<keyword>Carbazoles/therapeutic use</keyword>
	<keyword>Carbazoles/administration &amp; dosage</keyword>
	<keyword>Child</keyword>
	<keyword>Child , Preschool</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>Female</keyword>
	<keyword>Heart Failure , Congestive/etiology</keyword>
	<keyword>Heart Failure , Congestive/drug therapy</keyword>
	<keyword>Heart Failure , Congestive/blood</keyword>
	<keyword>Human</keyword>
	<keyword>Infant</keyword>
	<keyword>Infant , Newborn</keyword>
	<keyword>Male</keyword>
	<keyword>Natriuretic Peptide , Brain/blood</keyword>
	<keyword>Placebos</keyword>
	<keyword>Propanolamines/therapeutic use</keyword>
	<keyword>Propanolamines/administration &amp; dosage</keyword>
	<keyword>Prospective Studies</keyword>
	<keyword>Support , Non-U.S. Gov't</keyword>
	<keyword>Treatment Outcome</keyword>
	<keyword>Ventricular Dysfunction/drug therapy</keyword>
	<keyword>Ventricular Dysfunction/complications</keyword>
	<keyword>Ventricular Dysfunction/blood</keyword>
	<keyword>Ventricular Function/drug effect</keyword>
	<keyword>Ventricular Remodeling/drug effect</keyword>
</DOC>